ReviewJournal of thoracic disease2018
A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
Open access · hybridAbstract readReview
In one paragraph
Review in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 48 citations in OpenAlex.
- Osimertinib induces reversible cardiac dysfunction through the GATA4-MYLK3-MYL2 axis.European heart journal · 2026Article
- Beyond tobacco: understanding the growing burden of lung adenocarcinoma in women.Oncology reviews · 2026Review
- Design and investigation of novel iridoid-based peptide conjugates for targeting EGFR and its mutants L858R and T790M/L858R/C797S: an in silico study.Molecular diversity · 2025Article
- The Role and Therapeutic Potential of Non-coding RNAs in Resistance to EGFR - TKIs Targeted Therapy for Non-small Cell Lung Cancer.Current medicinal chemistry · 2025Review
- In vitro evidence for the potential of EGFR inhibitors to decrease the TGF-β1-induced dispersal of circulating tumour cell clusters mediated by EGFR overexpression.Scientific reports · 2024Article
- Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs.Therapeutic advances in medical oncology · 2024Review
- Real-World Data Presenting the Descriptive Analysis of the Use of Tyrosine Kinase Inhibitors (TKIs) Among Metastatic Non-Small-Cell Lung Cancer (mNSCLC) Patients in Qatar: A Nationwide Retrospective Cohort Study.Clinical Medicine Insights. Oncology · 2024Article
- Instability Mechanism of Osimertinib in Plasma and a Solving Strategy in the Pharmacokinetics Study.Frontiers in pharmacology · 2022Article
- Microfluidic Single-Cell Proteomics Assay Chip: Lung Cancer Cell Line Case Study.Micromachines · 2021Article
- Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment.BMC pulmonary medicine · 2021Article
- Generation of osimertinib-resistant cells from epidermal growth factor receptor L858R/T790M mutant non-small cell lung carcinoma cell line.Journal of the Chinese Medical Association : JCMA · 2021Article
- Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positiveClinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Exceptional Response of a Large and Symptomatic EGFR-Mutant Brain Metastasis to Osimertinib: Case Report and Review of the Literature.JCO precision oncology · 2021Review
- Levels of plasma glycan-binding auto-IgG biomarkers improve the accuracy of prostate cancer diagnosis.Molecular and cellular biochemistry · 2021Article
- Osimertinib in combination with bevacizumab inTranslational lung cancer research · 2020Article
- Rab8 and Rabin8-Mediated Tumor Formation by Hyperactivated EGFR Signaling via FGFR Signaling.International journal of molecular sciences · 2020Article
- Real-world treatment patterns and survival in stage IV non-small-cell lung cancer in Canada.Current oncology (Toronto, Ont.) · 2020Article
- Rapid and Sensitive Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDI-IM-MS/MS Assay.Cancers · 2020Article
- Analysis of Patient Preferences in Lung Cancer - Estimating Acceptable Tradeoffs Between Treatment Benefit and Side Effects.Patient preference and adherence · 2020Article
- Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.British journal of cancer · 2019Review
Corrections and comments
- Commented on by
- Commented on byOsimertinib for2019
- Commented on by
- Commented on by
Authors and funding
12 authors at 6 institutions in 5 countries.
Tao JiangDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.
Chunxia SuDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.
Shengxiang RenDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.
Federico CappuzzoDirector Oncology and Hematology Department, AUSL Romagna, Viale Randi 5, Ravenna, Italy.
Gaetano RoccoDepartment of Thoracic Surgery and Oncology, National Cancer Institute, Pascale Foundation, Naples, Italy.
Joshua D PalmerDepartment of Radiation Oncology, The James Cancer Hospital and Solove Research Institute at the Ohio State University Wexner Medical Center, Columbus, OH, USA.
Nico van ZandwijkUniversity of Sydney, Concord Repatriation General Hospital, Concord, NSW, Australia.
Fiona BlackhallInstitute of Cancer Sciences, University of Manchester, and Christie Hospital National Health Service Foundation Trust, Manchester, UK.
Xiuning LeDepartment of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Nathan A PennellDepartment of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
Caicun ZhouDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.
written on behalf of the AME Lung Cancer Collaborative Group
Tongji University · CNNational Health Service · GBAzienda Unità Sanitaria Locale Della Romagna · ITCleveland Clinic · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USThe University of Sydney · AU
Funding
Paul Calabresi Clinical Oncology AwardK12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI David S. Hong, Scott Kopetz · 2000 to 2026
$14.0MNCI NIH HHS K12 CA088084
Abstract
The first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have brought substantial clinical benefit to patients with advanced non-small cell lung cancer (NSCLC) and sensitizing
Indexed as
acquired resistanceEGFR T790MNon-small cell lung cancer (NSCLC)osimertinib
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.